Table 2.
PPIs utilization prescriptions patterns per prescription (n = 80,365).
| Variable | n | % | 95 % CI |
|---|---|---|---|
| Types of prescribed PPIs | |||
| Omeprazole | 9681 | 12.0 | 11.82–12.27 |
| Esomeprazole | 70,684 | 88.0 | 87.73–88.18 |
| Duration of PPIs use | |||
| 7 days or less | 27,265 | 33.9 | 33.60–34.25 |
| >7–21 days | 6495 | 8.1 | 7.89–8.27 |
| >21–42 | 5680 | 7.1 | 6.89–7.24 |
| More than 42 days | 8061 | 10.0 | 9.82–10.24 |
| Not reported | 32,864 | 40.9 | 40.55–41.23 |
| Administration routes | |||
| Oral | 56,446 | 70.2 | 69.92–70.55 |
| Sachet | 515 | 0.6 | 00.59–00.70 |
| Tablet | 51,069 | 63.5 | 63.21–63.88 |
| Suspension | 3016 | 3.8 | 3.62–3.89 |
| Capsule | 1846 | 2.3 | 2.19–2.40 |
| Non-oral (Injection) | 23,919 | 29.8 | 29.45–30.08 |
| PPIs combination use (per prescription time) | |||
| One type only | 80,227 | 99.8 | 99.80–99.86 |
| Combination of PPIs | 138 | 0.17 | 00.14–00.20 |
| Strength of dose | |||
| Low dose | 51 | 0.1 | 00.05–00.08 |
| Standard dose | 20,865 | 26.0 | 25.66–26.27 |
| High dose | 59,449 | 73.9 | 73.67–74.28 |
| PPIs indications | |||
| Peptic ulcer disease | 909 | 1.1 | 1.06–1.21 |
| Gastroesophageal reflux disease | 2217 | 2.8 | 2.65–2.87 |
| H. pylori | 78 | 0.1 | 00.08–00.12 |
| Esophagitis | 370 | 0.5 | 00.41–00.51 |
| Not reported | 76,791 | 95.5 | 95.41–95.69 |
| Drug-drug interactions | |||
| Potential DDIs with PPIs | 24,575 | 30.6 | 30.26–30.90 |
| PPIs with Atorvastatin | 12,006 | 48.9 | 48.23–49.48 |
| PPIs with Clopidogrel | 8387 | 34.1 | 33.54–34.72 |
| Other drugs | 4182 | 17.0 | 16.55–17.49 |
| No potential DDIs with PPIs | 55,790 | 69.4 | 69.10–69.74 |
*n: total number of observations; CI: confidence interval; SD: standard deviation; PPIs: proton pump inhibitors; H. pylori: Helicobacter pylori; DDIs: drug-drug interactions.